bupropion has been researched along with Acute Coronary Syndrome in 7 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
Excerpt | Relevance | Reference |
---|---|---|
" Bupropion hydrochloride has proven efficacy as a smoking cessation aid, but data regarding its safety and efficacy in ACS patients are limited." | 9.15 | Bupropion for smoking cessation in patients with acute coronary syndrome. ( Chasid, M; Elitzur, Y; Lev, I; Lotan, C; Ouzan, E; Planer, D; Pugatsch, T; Rom, M; Sharon, N, 2011) |
" We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD)." | 8.89 | Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. ( Eisenberg, MJ; Grandi, SM; Shimony, A, 2013) |
"To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion." | 7.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
" We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD)." | 4.89 | Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. ( Eisenberg, MJ; Grandi, SM; Shimony, A, 2013) |
"To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion." | 3.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Moiz, A | 1 |
Eisenberg, MJ | 3 |
Franck, C | 1 |
Filion, KB | 1 |
Grandi, SM | 1 |
Shimony, A | 1 |
Landau, J | 1 |
Ajani, AE | 1 |
Carney, RM | 1 |
Freedland, KE | 1 |
Planer, D | 1 |
Lev, I | 1 |
Elitzur, Y | 1 |
Sharon, N | 1 |
Ouzan, E | 1 |
Pugatsch, T | 1 |
Chasid, M | 1 |
Rom, M | 1 |
Lotan, C | 1 |
Svanström, H | 1 |
Pasternak, B | 1 |
Hviid, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial[NCT00794573] | Phase 3 | 302 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
Mindfulness-Based Cognitive Therapy Delivered Via Group Videoconferencing for Acute Coronary Syndrome Patients With Elevated Depression Symptoms[NCT03878160] | 27 participants (Actual) | Interventional | 2018-07-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
7-day point prevalence abstinence at week 12, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 12 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 86 |
Placebo | 55 |
7-day point prevalence abstinence at week 24, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 24 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 70 |
Placebo | 49 |
7-day point prevalence abstinence at week 4, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 4 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 90 |
Placebo | 57 |
7-day point prevalence abstinence at week 52, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 52 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 59 |
Placebo | 44 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 12. (NCT00794573)
Timeframe: 12 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 66 |
Placebo | 45 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 24. (NCT00794573)
Timeframe: 24 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 53 |
Placebo | 39 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 4. (NCT00794573)
Timeframe: 4 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 78 |
Placebo | 49 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 52. (NCT00794573)
Timeframe: 52 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 46 |
Placebo | 32 |
(NCT00794573)
Timeframe: 12 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 115 |
Placebo | 93 |
(NCT00794573)
Timeframe: 24 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 99 |
Placebo | 84 |
(NCT00794573)
Timeframe: 4 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 130 |
Placebo | 113 |
(NCT00794573)
Timeframe: 52 weeks
Intervention | Participants (Count of Participants) |
---|---|
Varenicline | 85 |
Placebo | 75 |
This is a 14-item scale that measures empathy. The scoring scale ranges from 0, does not describe me well, to 4, describes me very well. The score values range from 0-56, where high values represent higher levels of empathy and lower values represent lower levels of empathy. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 41 |
Women and Men, >2 Years, Individual Interview | 39 |
Women and Men, Lifetime History of ACS, Individual Interview | 45 |
This is a 3-item scale that measures health behaviors. The scoring scale ranges from 1, none of the time, to 6, all of the time. The scoring values range from 3-18, where higher values represent good health behavior and lower values represent poor health behavior. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 11 |
Women and Men, >2 Years, Individual Interview | 10 |
Women and Men, Lifetime History of ACS, Individual Interview | 13 |
This is a 9-item scale that measures depression. The scoring scale ranges from 0, not at all, to 3, nearly every day. The scoring values range from 0-18, where high values represent higher levels of depression and lower values represent lower levels of depression. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 10.5 |
Women and Men, >2 Years, Individual Interview | 16 |
Women and Men, Lifetime History of ACS, Individual Interview | 1.5 |
This is a 4-item scale that measures and evaluates physical health. The scoring scale ranges from 5, without any difficulty, to 1, unable to do. The scoring values range from 4-20, where high values represent good physical function and low values represent poor physical function. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 18 |
Women and Men, >2 Years, Individual Interview | 12 |
Women and Men, Lifetime History of ACS, Individual Interview | 20 |
This is a 4-item scale that measures stress. The scoring scale ranges from 0,never, to 4, very often. The scale values range from 0-16 with higher values representing higher levels of individual stress and lower values representing lower levels of individual stress. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 12 |
Women and Men, >2 Years, Individual Interview | 14 |
Women and Men, Lifetime History of ACS, Individual Interview | 6 |
This is a 20-question scale, composed of 2, 10-item scales that measure positive and negative affect. The scoring scale ranges from 1, very slightly or not at all, to 5, extremely. For this study, we will only use the positive affect sub-scale. The scale values for the positive affect sub-scale range from 10-50. Higher values on the positive affect scale represent higher levels of positive affect, whereas, lower values on the negative affect scale represent lower levels of positive affect. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 22 |
Women and Men, >2 Years, Individual Interview | 26 |
Women and Men, Lifetime History of ACS, Individual Interview | 34 |
This is a 22-item scale that measures rumination. The scoring scale ranges from 1,almost never, to 4, almost always. The score values range from 22 to 88, where higher values represent higher levels of rumination and lower values represent lower levels of rumination. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 41 |
Women and Men, >2 Years, Individual Interview | 51.5 |
Women and Men, Lifetime History of ACS, Individual Interview | 31 |
This is a 16-item scale that measures views toward the self and others. This measure consists of four sub-scales with four items each. The sub-scales measure positive views toward self, negative views toward self, positive views toward others, and negative views toward other. Only the positive-other sub-scale was used. The scoring scale ranges from 1, very slightly or not at all to 5, extremely, with sub-scale scores ranging from 4-20. Higher values represent higher levels of positive feelings toward others, and lower values represent lower levels of positive feelings toward others. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 15 |
Women and Men, >2 Years, Individual Interview | 12.5 |
Women and Men, Lifetime History of ACS, Individual Interview | 16 |
This is a 12-item scale that measures health-related quality of life. The scoring scale from item 1 ranges from 1, excellent to 5, poor. The scoring scale for items 2 and 3 ranges from 1, limit you a lot to 3, not limit you at all. The scoring scale for questions 5-7 is represented by 1, yes or 2, no. The scoring scale for item 8 ranges from 1, not at all, to 5, extremely. The scoring scale for items 9-11 ranges from 1, all of the time, to 6, none of the time. The scoring scale for item 12 ranges from 1, all of the time to 5, none of the time. The total scoring values range from 12- 47, where higher values represent a higher quality of life and lower values represent a lower quality of life. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 26 |
Women and Men, >2 Years, Individual Interview | 22 |
Women and Men, Lifetime History of ACS, Individual Interview | 40 |
This is a 15-item measure that measures mindfulness. This scale has five sub-scales: observing, describing, acting with awareness, accepting without judgment, and non-reactivity. The scoring scale ranges from 1, never or very rarely true to 5, very often or always true. Scale values range from 3-15 for each sub-scale, with higher values representing greater levels of individual mindfulness and lower values representing lowers levels of individual mindfulness. There is no total score for the measure; only individual sub-scales are reported. Data collection for this measurement is cross-sectional, and is collected during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) | ||||
---|---|---|---|---|---|
Observing | Describing | Acting with awareness | Accepting without judgment | Nonreactivity | |
Women and Men, <2 Years, Individual Interview | 8 | 11 | 11 | 11 | 11 |
Women and Men, >2 Years, Individual Interview | 9 | 9 | 9 | 8 | 9.5 |
Women and Men, Lifetime History of ACS, Individual Interview | 10 | 13 | 10 | 14 | 14 |
This portion of the individual interview will focus on exploring changes experienced after an ACS, such as psychosocial changes and health behavior changes. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Positive health behavior changes | Adaptive perspectives | Emotional improvements | Social improvements | Activity limitations | Negative physical symptoms | Emotional problems | Social problems | Health behavior challenges | |
Women and Men, <2 Years, Individual Interview | 3 | 1 | 0 | 1 | 5 | 5 | 3 | 3 | 2 |
Women and Men, >2 Years, Individual Interview | 3 | 0 | 1 | 0 | 7 | 8 | 8 | 2 | 5 |
Women and Men, Lifetime History of ACS, Individual Interview | 10 | 5 | 1 | 5 | 4 | 6 | 6 | 4 | 0 |
This portion of the individual interview will focus on exploring ACS patients who had perspectives on participating in a remote dried blood spot procedure. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The criteria used to determine the outcome measure is the number of participants upon interview who reported any type of perspective on participating in a remote dried blood spot procedure (self-collection of dried blood spot via finger-prick). Please note that the number of perspectives reported for each theme can exceed the number of people per group because each participant reported multiple perspectives (e.g., both pros and cons of videoconferencing). (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||
---|---|---|---|
Willing to complete DBS | Would need training | Would want more information about the rationale | |
Women and Men, <2 Years, Individual Interview | 5 | 2 | 5 |
Women and Men, >2 Years, Individual Interview | 7 | 5 | 4 |
Women and Men, Lifetime History of ACS, Individual Interview | 8 | 2 | 6 |
This portion of the individual interview will focus on exploring patients' perspectives toward an MBCT treatment approach. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||
---|---|---|---|
Willing to get help | Willing to participate in a group program | Positive reaction to mindfulness | |
Women and Men, <2 Years, Individual Interview | 3 | 3 | 4 |
Women and Men, >2 Years, Individual Interview | 8 | 6 | 7 |
Women and Men, Lifetime History of ACS, Individual Interview | 8 | 8 | 7 |
This portion of the individual interview will focus on exploring perspectives regarding videoconferencing intervention delivery. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. Identified themes are reported, and the criteria used to determine the outcome measure is the number of participants upon interview who reported expressed each theme. (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||||
---|---|---|---|---|---|
Willing to try videoconferencing | Logistical benefits | Social benefits | Technology limitations | Social limitations | |
Women and Men, <2 Years, Individual Interview | 3 | 5 | 2 | 2 | 2 |
Women and Men, >2 Years, Individual Interview | 7 | 5 | 1 | 5 | 1 |
Women and Men, Lifetime History of ACS, Individual Interview | 8 | 7 | 1 | 2 | 4 |
3 reviews available for bupropion and Acute Coronary Syndrome
Article | Year |
---|---|
Smoking Cessation in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Behavior Therapy; Bupropion; Cardiac Rehabilitation; Counseling; Electronic | 2018 |
Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Bupropion; Cardiovascular Diseases; Female; Follow-Up Studies; | 2013 |
Treatment-resistant depression and mortality after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Therapy; | 2009 |
1 trial available for bupropion and Acute Coronary Syndrome
Article | Year |
---|---|
Bupropion for smoking cessation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Bupropion; Counseling; Dopamine Uptake Inhibitors; Double-Blind Method; Fem | 2011 |
3 other studies available for bupropion and Acute Coronary Syndrome
Article | Year |
---|---|
Initiation of Varenicline in People Hospitalized for Acute Coronary Syndrome Who Smoke.
Topics: Acute Coronary Syndrome; Benzazepines; Bupropion; Cognition; Humans; Quinoxalines; Smoking; Smoking | 2023 |
Bupropion and bradycardia.
Topics: Acute Coronary Syndrome; Adrenergic Agents; Anti-Arrhythmia Agents; Atropine; Bradycardia; Bupropion | 2008 |
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Benzazepines; Bupropion; Cardiovascular Dise | 2012 |